title: CRISPR/Cas9 Technology Targeting Fas Gene Protects Mice From Concanavalin-A Induced Fulminant Hepatic Failure.
abstract: Fulminant hepatic failure is a life-threatening disease which occurs in patients without preexisting liver disease. Nowadays, there is no ideal therapeutic tool in the treatment of fulminant hepatic failure. Recent studies suggested that a novel technology termed CRISPR/Cas9 may be a promising approach for the treatment of fulminant hepatic failure. In this project, we have designed single chimeric guide RNAs specifically targeting the genomic regions of mouse Fas gene. The in vitro and in vivo effects of sgRNAs on the production of Fas protein were examined in cultured mouse cells and in a hydrodynamic injection-based mouse model, respectively. The in vivo delivery of CRISPR/Cas9 could maintain liver homeostasis and protect hepatocytes from Fas-mediated cell apoptosis in the fulminant hepatic failure model. Our study indicates the clinical potential of developing the CRISPR/Cas9 system as a novel therapeutic strategy to rescue Concanavalin-A-induced fulminant hepatic failure in the mouse model. J. Cell. Biochem. 118: 530-536, 2017. © 2016 Wiley Periodicals, Inc.
authors: School of Biomedical Sciences, The Chinese University of Hong Kong, Shatin, New Territories, Hong Kong, P. R. China.
authors: Wei-Cheng
authors: WC
authors: Liang
authors: Key Laboratory of Gene Engineering of Ministry of Education and State Key Laboratory of Biocontrol, School of Life Sciences, Sun Yat-Sen University, Guangzhou, P. R. China.
authors: Pu-Ping
authors: PP
authors: Liang
authors: School of Biomedical Sciences, The Chinese University of Hong Kong, Shatin, New Territories, Hong Kong, P. R. China.
authors: Cheuk-Wa
authors: CW
authors: Wong
authors: School of Biomedical Sciences, The Chinese University of Hong Kong, Shatin, New Territories, Hong Kong, P. R. China.
authors: Tzi-Bun
authors: TB
authors: Ng
authors: Key Laboratory of Gene Engineering of Ministry of Education and State Key Laboratory of Biocontrol, School of Life Sciences, Sun Yat-Sen University, Guangzhou, P. R. China.
authors: Jun-Jiu
authors: JJ
authors: Huang
authors: Stem Cells and Regenerative Medicine Laboratory, Lui Che Woo Institute of Innovative Medicine, Li Ka Shing Institute of Health Sciences, The Chinese University of Hong Kong, Prince of Wales Hospital, Shatin, Hong Kong, P. R. China.|Department of Orthopaedics and Traumatology, The Chinese University of Hong Kong, Prince of Wales Hospital, Shatin, Hong Kong, P. R. China.|Shenzhen Research Institute, The Chinese University of Hong Kong, Shenzhen, P. R. China.
authors: Jin-Fang
authors: JF
authors: Zhang
authors: School of Biomedical Sciences, The Chinese University of Hong Kong, Shatin, New Territories, Hong Kong, P. R. China.|The Nethersole School of Nursing, The Chinese University of HongKong, Shatin, Hong Kong, P. R. China.
authors: Mary Miu-Yee
authors: MM
authors: Waye
authors: School of Pharmaceutical Sciences, Southern Medical University, Guangzhou, P. R. China.
authors: Wei-Ming
authors: WM
authors: Fu
mesh_terms: D000818:Animals; D017209:Apoptosis / Q000235:genetics; D002460:Cell Line; D064112:Clustered Regularly Interspaced Short Palindromic Repeats; D003208:Concanavalin A / Q000633:toxicity*; D004195:Disease Models, Animal; D018390:Gene Targeting; D022781:Hepatocytes / Q000378:metabolism; D017114:Liver Failure, Acute / Q000139:chemically induced / Q000235:genetics / Q000378:metabolism / Q000517:prevention & control; D051379:Mice; D008813:Mice, Inbred ICR; D019014:fas Receptor / Q000235:genetics* / Q000378:metabolism
chemical_list: C491899:Fas protein, mouse; D019014:fas Receptor; D003208:Concanavalin A
keywords: CRISPR/Cas9; FULMINANT HEPATIC FAILURE; Fas GENE; GENE THERAPY